Background -Corticosteroids suppress disease activity in pulmonary sarcoidosis and their use produces symptomatic, radiographic, and functional improvement. There is, however, uncertainty regarding their effects on the overall natural history of the condition and long term benefit is unproven.
Methods -Patients with pulmonary radiographic shadowing due to sarcoidosis were recruited in a multicentre study. Those who, in the first six months after entry to the study, neither required prednisolone for symptoms nor showed radiographic improvement were allocated at six months to receive either long term steroid treatment (group L) or selective treatment (group S), with regular assessment over the subsequent five years. Patients in group L were scheduled to receive steroid treatment for at least 18 months with the policy of achieving and maintaining maximal radiographic clearing, while in group S treatment was reserved for use only if warranted by later development of symptoms or deteriorating lung function.
Symptoms, radiographic appearances, and respiratory function were assessed periodically during the study. Results -One hundred and forty nine patients were followed: 33 required prednisolone for troublesome symptoms within six months of entry and 58 showed radiographic improvement over this period. The remaining 58 patients were allocated to groups L (n = 27) and S (n = 31). Patients in group L showed greater improvements in symptoms, respiratory function, and radiographic appearances than those in group S, although the differences were not large. After adjusting for differences at the time of allocation, the average difference in vital capacity between groups L and S at final assessment was The optimal treatment of patients with pulmonary sarcoidosis is not known. There is general agreement on the effect of corticosteroids in suppressing the acute consequences ofwidespread pulmonary granulomas, but their effects on the overall natural history and any long term benefits are much less certain. Some authorities advocate long term use in order to prevent chronic lung damage,'2 while others are less convinced of benefit.3-5 Many of the previous studies performed to address this question may be criticised on the grounds that they were retrospective, uncontrolled, or included patients with only bilateral hilar lymphadenopathy where the prognosis without treatment is known to be good. Controlled studies5"-3 have generally failed to show an advantage of treatment when follow up has continued for a number of years. In most studies, however, steroids have been used in fixed treatment schedules from the time of presentation, while in clinical practice treatment is often deferred pending possible spontaneous improvement and the duration and doses of steroid are tailored to the progress of the individual.
There appeared therefore to be a need for a study of the long term effects of steroids in pulmonary sarcoidosis: (a) which concentrated on those patients whose condition was not showing rapid spontaneous resolution; (b) where the treatment could be adjusted (increased, maintained or restarted) with the aim of achieving and maintaining radiographic appearances that were as normal as possible; and (c) where comparison was made with a similar group who were untreated. This last condition implies that such a study would be possible only after excluding patients who require steroid treatment for troublesome symptoms.
A protocol was developed, incorporating these points, to assess whether use of steroids for pulmonary sarcoidosis improved the long term outcome in terms of symptoms, radiographic appearances, and pulmonary function. The period of observation before treatment and the recommended doses and duration of treatment were based on the most frequent clinical practice, as judged by answers to a preliminary questionnaire sent to all UK consultant respiratory physicians.
Methods

PROTOCOL
Patients were recruited on a multicentre basis by consultant members of the British Thoracic Society (BTS). Those eligible were newly presenting patients with sarcoidosis and pulmonary shadowing who gave informed consent; they could be ofeither sex and were aged between 18 and 60 years. Patients presenting with bilateral hilar lymphadenopathy alone and no pulmonary shadowing were not recruited, but they became eligible later if pulmonary shadowing developed. Participating physicians were encouraged to obtain histological support for the diagnosis by taking an appropriate biopsy sample such as bronchial, lung, lymph node, liver or skin, the latter including a response to Kveim reagent. Patients with a diagnosis of sarcoidosis and characteristic radiographic pulmonary shadowing plus bilateral hilar lymphadenopathy were accepted into the study without histological support, but diffuse shadowing alone without histological evidence was not acceptable.
Patients were excluded from the study if at the time of presentation any of the following applied: (1) corticosteroids were required for non-respiratory sarcoidosis -for example, hypercalcaemia, neurological, cardiac, renal or ophthalmic involvement (steroid eye drops alone were allowed); (2) steroids were relatively contraindicated -for example, history of peptic ulcer, diabetes or hypertension; (3) concurrent asthma, chronic obstructive pulmonary disease, or treatment with an inhaled steroid; (4) Regular assessments comprised a simple questionnaire, measurements of lung function, and a posteroanterior chest radiograph. Assessments were planned in all patients at entry, three and six months after entry, and subsequently at intervals varying between one and 12 months for a total period of five years from allocation. The precise schedule of assessments varied between groups but was similar for the comparative groups L and S.
The symptomatic assessment included grading ofbreathlessness ofincreasing severity from 0 to 4 (modified from the MRC grades).
Lung function was assessed by spirometric measurements of forced expiratory volume in one second (FEV,) and vital capacity (VC) Radiographic changes were assessed in the first instance by the participating physician. All radiographs were subsequently graded by two physicians (MFM and WGM) using a system developed specifically for this study. In brief, for each radiograph the two readers agreed an assessment of shadowing of one or more of four types: R = reticulonodular (small rounded and/or fine linear opacities with mean diameter <5 mm); M = macronodular (discrete nodules with mean diameter >5 mm); C = confluent (patchy homogeneous alveolar shadowing simulating consolidation); F = "fibrotic" (irregular linear opacities with or without distortion of the normal vascular pattern, contraction of lung tissue, cysts or bullae). Linear opacities in the absence of the other features were accepted as type F shadows only if they were persistent when films were reviewed in sequence. Shadowing was assessed in terms of extent and profusion, each on a scale from 0 to 4. An overall score for each type of shadowing was obtained by multiplying the extent and profusion scores; scores could therefore vary between 0 and 16. The presence or absence of lymphadenopathy, pleural and cardiac abnormalities on each radiograph was also noted. Throughout, the readers assessed radiographs of groups L and S together without knowledge of the allocation of individual patients.
The main analyses were based on breathlessness scores, lung function and radiographic scores obtained in each subject at the times of allocation and final assessment.
In addition, a combined "clinical score" defined prospectively in terms of breathlessness grade, functional, and radiographic data (table 1) was calculated from differences seen between allocation and final assessment. This represents an attempt to mimic the clinical situation by combining the different forms of information used in practice to assess whether or not a patient has improved on treatment.
Using the criteria specified in table 1, the "clinical score" for changes between allocation and final assessment could vary between -3 and 5-2 (0 5) 5 0 (1-5) [4] [5] [6] (1-8) 4 9 (1-6) L= long term treatment; S = selective treatment; 0 = observation group; P = prednisolone group. * Cryptogenic fibrosing alveolitis (2), lymphoma (1), uncertain (1). t Including one patient who underwent lung transplantation 3 years 5 months after allocation. t Including one patient who died 2 years 2 months after allocation.
+ 2, with a negative figure indicating an adverse outcome and 0 representing no change.
All histological material was reviewed without knowledge of the study groups by one individual (DNM) and graded as "compatible with sarcoidosis", "indeterminate", or negative. STATISTICAL 
METHODS
Differences between groups were compared using analysis of variance (ANOVA) for continuous variables and %2 tests for categorical variables. Analysis of covariance was used to compare the outcome in groups L and S. Results One hundred and eighty three patients were recruited to the study by 70 physicians over the period . Of these, 15 were excluded before allocation because of unwillingness to continue (n=3), use of steroids for other indications (n = 3), absence of pulmonary shadowing at entry (n = 2), and failure to attend for the first follow up appointment (n = 7). Of the remaining 168 patients, 35 were considered to require treatment with prednisolone at or within six months ofentry (group P). In 66 patients the physician reported no radiographic improvement after six months and these were allocated to groups L or S. In 67 patients the physician reported improvement at six months and these were therefore allocated to group 0. When the radiographs were assessed subsequently it was apparent that 15 patients had been allocated inappropriately to groups L, S, or 0. In addition, four patients were withdrawn later because of a change of diagnosis, leaving 149 who represent the subject of this report (table 2, fig 1) . Inevitably there were some further defaulters during the follow up period, particularly among patients whose condition had improved and who were not receiving regular treatment, but 129 patients were followed for at least four years (table 2) .
For the final analysis, data on all patients in each study group as defined in table 2 have been included using five year follow up results where available or the latest information obtained in those who had defaulted before five years. In some individuals in whom information at five years had not been obtained because of earlier defaulting, final assessments were subsequently obtained more than five years after allocation following repeated enquiries and requests to the physicians and patients concerned. For these reasons, the average follow up in all groups was close to five years (table 2) . DEMOGRAPHIC DATA (table 3) The subjects recruited to the study showed a male preponderance in a ratio of 1 6:1 and only nine of the 149 were non-white. Patients in group 0 were notably younger on average than other patients in the study. Overall, 53% of subjects had never smoked and only 15% were current smokers with the highest proportion of current smokers in group 0.
FEATURES AT ENTRY AND ALLOCATION
Clinical, radiographic, functional, and histological data at entry and allocation are summarised in tables 4 and 5. Histological support for the diagnosis was obtained in 79% of the patients. No supportive histological information was available in 31 patients, all of whom had characteristic radiographic features of bilateral hilar lymphadenopathy plus pulmonary shadowing.
Respiratory symptoms were the main presenting feature in most of the patients in groups L, S, and P, while in group 0 erythema nodosum was an equally common main feature. Table 8 shows clinical, radiographic, and functional data at the time of the final assessment 
CRITICISMS OF THE PRESENT STUDY
The study was designed on a multicentre basis because no one centre is likely to see sufficient patients of the type studied here to mount a large study. Since, however, our patients were under investigation and treatment by physicians in several hospitals, we were able to gather only relatively simple information regarding symptoms and lung function. Moreover, we had no control over the quality of the radiographs or measurements of lung function in the different centres; in most cases, however, patients were followed up in a single centre throughout the study. Although the study was controlled it was not truly randomised as suitable patients were allocated alternately to groups L and S. Since the allocation was performed centrally, however, participating physicians could not be aware of the allocation in advance and it seems unlikely that this could have influenced the results.
We chose not to include a placebo treated group as it was considered unrealistic to maintain placebo treatment for the duration of the study. As in other studies, it was not practicable to include in the two main comparative groups those patients who initially were most seriously affected (group P). In principle, the more severely affected individuals (group P) might have the greatest capacity for improvement and consequently the need to restrict the main comparative study to those with stable and generally less severe pulmonary disease may result in underestimation of the longer term benefit of steroid treatment.
Unfortunately, by chance the two main study groups L and S showed some imbalance at allocation in terms of sex distribution and the presence of recognisable F type shadows on the chest radiograph. We allowed for this by repeating the comparison after adjustment for variables at the time of allocation which it was considered might have influenced the results.
Support for the diagnosis from biopsy samples was obtained in 79% of the patients. Entry to the study was based essentially on clinical criteria and for this reason four patients had to be excluded from analysis because the diagnosis was later revised. In all other instances, however, there was no reason to question the diagnosis of sarcoidosis in those in whom biopsy samples had been non-diagnostic or were not obtained.
Despite strenuous efforts (including, in one instance, obtaining information from New Zealand on a subject who had emigrated), complete follow up could not be obtained in all patients. In the two main study groups, however, information was available for at least four years of follow up in all but four subjects.
We do not claim that the population studied here is necessarily representative of the total population ofpatients with sarcoidosis and pulmonary shadowing. In particular, physicians may have been deterred from entering patients with more severe disease at presentation; if such patients are relatively underrepresented, however, the proportion of patients with pulmonary sarcoidosis in whom a decision about steroid treatment is necessary after a period of observation is even less than the 40% found in the present study. below the fifth centile at the time of allocation. The frequency of airway obstruction increased during the study and was slightly higher in all groups at the final assessment compared with that at allocation (tables 5 and 8). There was a correlation between FEV,NC ratio and F type shadows (unpublished data), suggesting that the increasing prevalence of airway obstruction was largely related to distortion associated with increasing fibrosis, a conclusion which accords with clinical experience in chronic sarcoidosis.
EFFECT OF CORTICOSTEROIDS
The main aim of this study was to assess whether a treatment policy of prolonged use of corticosteroids in patients with pulmonary sarcoidosis resulted in less long term damage as assessed by symptoms, function, and chest radiography. The general trends in groups L and S suggest that this was indeed the case. The data in these two groups have been analysed on the basis of the intention to treat, retaining the original group allocation -that is, group L including the two subjects who did not receive steroids and group S including the six who did. The comparison is therefore between two treatment policies rather than simply an assessment ofthe long term effects ofsteroids. We examined whether improvements in patients in group S were confined to the six patients who received steroids and this appeared not to be the case. Indeed, these individuals showed a greater increase in radiographic F score between allocation and final assessment than did the remaining 25 individuals (p<002).
The difference between patients in groups L and S is most clearly evident when the various methods of assessment were combined in a pragmatic "clinical score" (fig 2) . Similar trends were seen in each of the functional, clinical, and radiographic indices separately, although only spirometric volumes remained statistically significant when the comparison was made after adjustment for factors at allocation which might have influenced the results.
We estimated that the average improvement in spirometric volumes resulting from long term steroid treatment in this population of patients was 9% of predicted. Inevitably this was achieved at a certain "cost" related to the treatment. Steroid treatment often proved to be prolonged, even in patients in group L in whom the treatment had been initiated for reasons other than symptomatic deterioration. The various side effects of treatment were as might have been expected and were seen in approximately two thirds of patients. In only two instances were they sufficiently severe to necessitate discontinuation of treatment, how-ever. The anticipated weight gain was seen with a significant difference between groups L and S in the first year but, interestingly, a significant difference was not sustained at the time of final assessment.
In conclusion, our results in patients with pulmonary sarcoidosis and persistent radiographic shadowing support a small but definite long term advantage from prolonged treatment with corticosteroids. The results also emphasise the need for a period of observation before initiating treatment in those who do not require steroids for symptomatic relief.
The following physicians entered and/or supervised patients in the study: 
